SCHEMBL375474

SCHEMBL375474

CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 18/20 1.00
▸ HTR1B P28222 6/20 1.00
▸ DRD3 P35462 6/20 1.00
▸ HTR1A P08908 5/20 1.00
▸ DRD2 P14416 5/20 1.00
▸ HTR1D P28221 5/20 1.00
▸ CYP2D6 P10635 2/20 1.00
▸ HTR5A P47898 2/20 1.00
▸ HTR6 P50406 2/20 1.00
▸ HTR2B P41595 2/20 1.00
▸ CYP3A4 P08684 1/20 1.00
▸ CYP1A2 P05177 1/20 1.00
▸ HTR4 Q13639 1/20 1.00
▸ TMEM97 Q5BJF2 2/20 0.98
▸ ADRA2A P08913 1/20 0.98
▸ ADRA2B P18089 1/20 0.98
▸ ADRA2C P18825 1/20 0.98
▸ OPRM1 P35372 1/20 0.98
▸ OPRK1 P41145 1/20 0.98
▸ BLM P54132 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375475 1.00 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
Hydrochloric Acid SCHEMBL2719588 0.99 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
Hydrochloric Acid SCHEMBL2719586 0.99 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
Sb-258741 SCHEMBL4454954 0.88 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
Sb-258741 SCHEMBL4459020 0.88 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
SCHEMBL4298542 0.87 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
SCHEMBL4298546 0.87 HTR7 (1.00) HTR7HTR1BDRD3HTR1ADRD2
SCHEMBL5809435 0.87 HTR7 (0.78) HTR7HTR1BDRD3HTR1ADRD2
SCHEMBL14117920 0.86 HTR7 (0.77) HTR7HTR1BDRD3HTR1ADRD2
Hydrochloric Acid SCHEMBL14893193 0.85 HTR7 (0.77) HTR7HTR1BDRD3HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856156-B1 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES MEDIZINISCHE HOCHSCHULE HANNOVER MHH (DE) 2025-10-29 — — EP claimed
US-20220023257-A1 TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) 2022-01-27 — — US claimed
EP-2052251-B1 COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY JANSSEN PHARMACEUTICA NV (BE) 2019-08-07 — — EP claimed
US-8883808-B2 Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 — — US claimed
US-20090275563-A1 Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy BONAVENTURE PASCAL 2009-11-05 — — US claimed
US-20090270455-A1 Therapeutic agent for intestinal diseases and visceral pain AJINOMOTO CO., INC. (JP) 2009-10-29 — — US claimed
US-20050148632-A1 Therapeutic agent for intestinal diseases and visceral pain AJINOMOTO CO., INC. (JP) 2005-07-07 — — US claimed
EP-1541172-A1 REMEDY FOR INTESTINAL DISEASES AND VISCERAL PAIN Ajinomoto Co., Inc. (JP) 2005-06-15 — — EP claimed
EP-0912512-B1 SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 2003-04-02 — — EP claimed
US-6265408-B1 PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT SMITHKLINE BEECHAM PLC (GB) 2001-07-24 — — US claimed
WO-2000037082-A1 USE OF 5-HT7 RECEPTOR ANTAGONISTS FOR TREATING NEURONAL DEGENERATION RESULTING FROM ISCHEMIC EVENTS SMITHKLINE BEECHAM P.L.C. (GB) 2000-06-29 — — WO claimed
US-12623070-B2 Transcutaneous electrical spinal cord neuromodulator and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-12 — — US disclosed
US-20260078115-A1 ALIPHATIC ACID AMIDE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-03-19 — — US disclosed
EP-4710997-A2 ACCESSING SPINAL NETWORK TO ENABLE RESPIRATORY FUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-03-18 — — EP disclosed
US-20260060941-A1 ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-03-05 — — US disclosed
WO-2006039383-A2 SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-13 — — WO disclosed
US-20060069250-A1 Synthesis by chiral diamine-mediated asymmetric alkylation DENG XIAOHU 2006-03-30 — — US disclosed
US-20050148632-A1 Therapeutic agent for intestinal diseases and visceral pain AJINOMOTO CO., INC. (JP) 2005-07-07 — — US disclosed
EP-1541172-A1 REMEDY FOR INTESTINAL DISEASES AND VISCERAL PAIN Ajinomoto Co., Inc. (JP) 2005-06-15 — — EP disclosed
WO-2000037082-A1 USE OF 5-HT7 RECEPTOR ANTAGONISTS FOR TREATING NEURONAL DEGENERATION RESULTING FROM ISCHEMIC EVENTS SMITHKLINE BEECHAM P.L.C. (GB) 2000-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060941-A1 ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS PMP22, PRKX, GABRE HTR7 2959/4885HTR1B 1674/4885DRD3 1275/4885
US-20090270455-A1 Therapeutic agent for intestinal diseases and visceral pain VIP, VIPR2, GPR17 HTR7 6/4885HTR1B 164/4885DRD3 1845/4885
US-12623070-B2 Transcutaneous electrical spinal cord neuromodulator and uses thereof NCS1, CHRNA10, CHRNA4 HTR7 4064/4885HTR1B 1425/4885DRD3 1023/4885
US-20060069250-A1 Synthesis by chiral diamine-mediated asymmetric alkylation SRM, SMOX, DDC HTR7 2806/4885HTR1B 1217/4885DRD3 242/4885
US-20220023257-A1 TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES HTR7, MAPT, HTR1A HTR7 1/4885HTR1B 14/4885DRD3 319/4885
US-20050148632-A1 Therapeutic agent for intestinal diseases and visceral pain VIP, VIPR2, GPR17 HTR7 6/4885HTR1B 164/4885DRD3 1845/4885
US-20090275563-A1 Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy HTR7, HTR1A, HTR6 HTR7 1/4885HTR1B 11/4885DRD3 183/4885
US-20260078115-A1 ALIPHATIC ACID AMIDE DERIVATIVE HTR1D, HTR1A, HTR7 HTR7 3/4885HTR1B 6/4885DRD3 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback